Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018129332 - EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS

Publication Number WO/2018/129332
Publication Date 12.07.2018
International Application No. PCT/US2018/012605
International Filing Date 05.01.2018
IPC
C12N 5/0783 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
C12N 5/078 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
CPC
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/2875
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2875against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
C07K 16/2878
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2878against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
C12N 2501/2302
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
20Cytokines; Chemokines
23Interleukins [IL]
2302Interleukin-2 (IL-2)
Applicants
  • IOVANCE BIOTHERAPEUTICS, INC. [US]/[US]
Inventors
  • LOTZE, Michael, T.
  • RITTHIPICHAI, Krit
Agents
  • WALLS, Thomas, H.
  • DAVIS, Kenneth, J.
  • GRIFFIN, Gail, H.
  • CHAI, Deping
  • BRARDELL, Louis, W.
Priority Data
62/443,55606.01.2017US
62/460,47717.02.2017US
62/532,80714.07.2017US
62/567,15102.10.2017US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS
(FR) EXPANSION DE LYMPHOCYTES INFILTRANT LES TUMEURS (TIL) AVEC DES AGONISTES DE LA SUPERFAMILLE DES RÉCEPTEURS DU FACTEUR DE NÉCROSE TUMORALE (TNFRSF) ET DES COMBINAISONS THÉRAPEUTIQUES DE TIL ET D'AGONISTES DE TNFRSF
Abstract
(EN)
Methods of expanding tumor infiltrating lymphocytes (TILs) using a tumor necrosis factor receptor superfamily (TNFRSF) agonist, such as a 4- IBB agonist, a CD27 agonist, a glucocorticoid-induced TNF receptor-related agonist, an OX40 agonist, a HVEM agonist, or a CD95 agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein. In addition, in some embodiments, therapeutic combinations of TILs and TNFRSF agonists useful in the treatment of diseases such as cancer, including compositions, uses, and dosing regimens thereof, are disclosed herein.
(FR)
L'invention concerne des procédés d'expansion de lymphocytes infiltrant les tumeurs (TIL) à l'aide d'un agoniste de la superfamille des récepteurs du facteur de nécrose tumorale (TNFRSF), tel qu'un agoniste de 4-IBB, un agoniste de CD27, un agoniste associé au récepteur du TNF induit par un glucocorticoïde, un agoniste d'OX40, un agoniste d'HVEM, ou un agoniste de CD95, et des utilisations de ces TIL expansés dans le traitement de maladies telles que le cancer. De plus, dans certains modes de réalisation, des combinaisons thérapeutiques de TIL et d'agonistes de TNFRSF utiles dans le traitement de maladies telles que le cancer, y compris des compositions, des utilisations et des schémas posologiques associés, sont décrites dans la description.
Latest bibliographic data on file with the International Bureau